Bioactive grade

Recombinant human IL-6 protein (Active) (ab9627)

Submit a review Q&A (1)References (7)

Key features and details

  • Expression system: Escherichia coli
  • Purity: > 98% SDS-PAGE
  • Endotoxin level: < 1.000 Eu/µg
  • Active: Yes
  • Suitable for: HPLC, SDS-PAGE, Functional Studies, Neutralising

Achieve higher consistency and quality standards with a premium grade bioactive protein

Product image
Recombinant human IL-6 protein (Active) (ab259381)
  • High batch-to-batch consistency
  • Optimal bioactivity
  • Guaranteed identical to human native proteins
  • >95% purity
  • Ultra-low endotoxin levels: <0.005 Eu/µg
  • Carrier and tag free

Description

  • Product name

    Recombinant human IL-6 protein (Active)
    See all IL-6 proteins and peptides

  • Biological activity

    Determined by its ability to stimulate the proliferation of mouse B9 cells.

  • Purity

    > 98 % SDS-PAGE.
    > 98% HPLC analyses. Sterile filtered.

  • Endotoxin level

    < 1.000 Eu/µg

  • Expression system

    Escherichia coli

  • Accession

    P05231

  • Protein length

    Full length protein

  • Animal free

    No

  • Nature

    Recombinant

    • Species

      Human

    • Sequence

      PVPPGEDSKD VAAPHRQPLT SSERIDKQIR YILDGISALR KETCNKSNMC ESSKEALAEN NLNLPKMAEK DGCFQSGFNE ETCLVKIITG LLEFEVYLEY LQNRFESSEE QARAVQMSTK VLIQFLQKKA KNLDAITTPD PTTNASLLTK LQAQNQWLQD MTTHLILRSF KEFLQSSLRA LRQM

    • Predicted molecular weight

      21 kDa

    • Amino acids

      29 to 212

    • Additional sequence information

      Full length mature protein without the signal peptide.

Associated products

Specifications

Our Abpromise guarantee covers the use of ab9627 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    HPLC

    SDS-PAGE

    Functional Studies

    Neutralising

  • Form

    Lyophilized
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. For long term storage it is recommended to add a carrier protein on reconstitution (0.1% HSA or BSA).

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

  • Reconstitution
    Reconstitute on arrival. Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-0.5 mg/ml.

General Info

  • Alternative names

    • Interleukin BSF 2
    • B cell differentiation factor
    • B cell stimulatory factor 2
    • B-cell stimulatory factor 2
    • BSF 2
    • BSF-2
    • BSF2
    • CDF
    • CTL differentiation factor
    • Cytotoxic T cell differentiation factor
    • Hepatocyte stimulating factor
    • Hepatocyte stimulatory factor
    • HGF
    • HSF
    • Hybridoma growth factor
    • Hybridoma growth factor Interferon beta-2
    • Hybridoma plasmacytoma growth factor
    • IFN-beta-2
    • IFNB2
    • IL 6
    • IL-6
    • IL6
    • IL6_HUMAN
    • Interferon beta 2
    • Interferon beta-2
    • Interleukin 6
    • Interleukin 6 (interferon beta 2)
    • Interleukin BSF 2
    • Interleukin-6
    see all

  • Function

    Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.

  • Involvement in disease

    Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
    Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.

  • Sequence similarities

    Belongs to the IL-6 superfamily.

  • Post-translational
    modifications

    N- and O-glycosylated.

  • Cellular localization

    Secreted.
  • Information by UniProt

Protocols

To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

Click here to view the general protocols

References (7)

Publishing research using ab9627? Please let us know so that we can cite the reference in this datasheet.

ab9627 has been referenced in 7 publications.

  • Tang Q  et al. Hippo pathway monomerizes STAT3 to regulate prostate cancer growth. Cancer Sci 113:2753-2762 (2022). PubMed: 35722967
  • Huang X  et al. IL-6/STAT3 Axis Activates Glut5 to Regulate Fructose Metabolism and Tumorigenesis. Int J Biol Sci 18:3668-3675 (2022). PubMed: 35813468
  • Jiang J  et al. Luteolin suppresses the growth of colon cancer cells by inhibiting the IL-6/STAT3 signaling pathway. J Gastrointest Oncol 13:1722-1732 (2022). PubMed: 36092354
  • Ni XF  et al. The hepatic microenvironment promotes lung adenocarcinoma cell proliferation, metastasis, and epithelial-mesenchymal transition via METTL3-mediated N6-methyladenosine modification of YAP1. Aging (Albany NY) 13:4357-4369 (2021). PubMed: 33495421
  • Domfeh SA  et al. Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling. BMC Complement Med Ther 21:161 (2021). PubMed: 34078370
  • Zhang W  et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J Immunother Cancer 8:N/A (2020). PubMed: 32581055
  • Lai X & Friedman A Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. BMC Syst Biol 11:70 (2017). PubMed: 28724377

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

Question

- Lagerung: was ist besser -20 oder -80?
- Auflösung von Lyophilisierung

Read More
Answer



Dieses Protein muss in 5-10mM Essigsäure (Acetic acid) aufgenommen werden damit eine volle Solubilisierung gewährleistet werden kann. Wir empfehlen eine Endkonzentration des Proteins von 0.1-0.5 mg/ml.

Danach kann es weiter mit PBS oder jedem anderen wässrige Puffer verdünnt werden. Das sollte den pH dann auch wieder auf physiologische Ebene zurückbringen

Nach dem Verdünnen empfehlen wir das Protein zu aliquotieren und bei -80C zu lagern, da das Protein aktiv ist.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com